Cisplatin and cyclophosphamide in advanced ovarian carcinoma: Activity and toxicity of an ambulatory regimen

M. Zambetti, L. Gianni, F. Di Re, G. Spatti, R. Fontanelli, A. Es cobedo, G. De Palo, G. Bonadonna

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Chemotherapy with cisplatin (CDDP, 90 mg/m2) and cyclophosphamide (CTX, 600 mg/m2) was administered to 54 consecutive patients with advanced epithelial ovarian cancer (37 stage III and 17 stage IV). In 51 patients, surgery was performed prior to chemotherapy. Of the 37 stage III patients, 13 had only minimal residual disease after surgical debulking. The overall response rate was 69%, with 44% patients achieving clinical (cCR; n = 2) or pathological (pCR; n = 20) complete response. Median follow-up and overall survival time was 26 months, and median CR duration was 30 months. CR was achieved in 6 of 14 patients (43%) who were partial responders after five cycles of chemotherapy and had continued treatment for three to five more cycles. Severe bone marrow toxicity or renal function impairment was never observed, but eight patients presented peripheral signs of dose-related neurotoxicity. These findings indicate that CDDP and CTX in combination are an effective treatment for patients with advanced ovarian carcinoma, and can be administered with tolerable toxicity. In selected cases, prolonged chemotherapy administration can result in durable complete remissions.

Original languageEnglish
Pages (from-to)199-203
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume13
Issue number3
Publication statusPublished - 1990

Fingerprint

Cyclophosphamide
Cisplatin
Carcinoma
Drug Therapy
Residual Neoplasm
Bone Marrow
Kidney
Survival
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cisplatin and cyclophosphamide in advanced ovarian carcinoma : Activity and toxicity of an ambulatory regimen. / Zambetti, M.; Gianni, L.; Di Re, F.; Spatti, G.; Fontanelli, R.; Es cobedo, A.; De Palo, G.; Bonadonna, G.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 13, No. 3, 1990, p. 199-203.

Research output: Contribution to journalArticle

Zambetti, M, Gianni, L, Di Re, F, Spatti, G, Fontanelli, R, Es cobedo, A, De Palo, G & Bonadonna, G 1990, 'Cisplatin and cyclophosphamide in advanced ovarian carcinoma: Activity and toxicity of an ambulatory regimen', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 13, no. 3, pp. 199-203.
Zambetti, M. ; Gianni, L. ; Di Re, F. ; Spatti, G. ; Fontanelli, R. ; Es cobedo, A. ; De Palo, G. ; Bonadonna, G. / Cisplatin and cyclophosphamide in advanced ovarian carcinoma : Activity and toxicity of an ambulatory regimen. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1990 ; Vol. 13, No. 3. pp. 199-203.
@article{8aa5b43009464759990c060a1e905b7e,
title = "Cisplatin and cyclophosphamide in advanced ovarian carcinoma: Activity and toxicity of an ambulatory regimen",
abstract = "Chemotherapy with cisplatin (CDDP, 90 mg/m2) and cyclophosphamide (CTX, 600 mg/m2) was administered to 54 consecutive patients with advanced epithelial ovarian cancer (37 stage III and 17 stage IV). In 51 patients, surgery was performed prior to chemotherapy. Of the 37 stage III patients, 13 had only minimal residual disease after surgical debulking. The overall response rate was 69{\%}, with 44{\%} patients achieving clinical (cCR; n = 2) or pathological (pCR; n = 20) complete response. Median follow-up and overall survival time was 26 months, and median CR duration was 30 months. CR was achieved in 6 of 14 patients (43{\%}) who were partial responders after five cycles of chemotherapy and had continued treatment for three to five more cycles. Severe bone marrow toxicity or renal function impairment was never observed, but eight patients presented peripheral signs of dose-related neurotoxicity. These findings indicate that CDDP and CTX in combination are an effective treatment for patients with advanced ovarian carcinoma, and can be administered with tolerable toxicity. In selected cases, prolonged chemotherapy administration can result in durable complete remissions.",
author = "M. Zambetti and L. Gianni and {Di Re}, F. and G. Spatti and R. Fontanelli and {Es cobedo}, A. and {De Palo}, G. and G. Bonadonna",
year = "1990",
language = "English",
volume = "13",
pages = "199--203",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Cisplatin and cyclophosphamide in advanced ovarian carcinoma

T2 - Activity and toxicity of an ambulatory regimen

AU - Zambetti, M.

AU - Gianni, L.

AU - Di Re, F.

AU - Spatti, G.

AU - Fontanelli, R.

AU - Es cobedo, A.

AU - De Palo, G.

AU - Bonadonna, G.

PY - 1990

Y1 - 1990

N2 - Chemotherapy with cisplatin (CDDP, 90 mg/m2) and cyclophosphamide (CTX, 600 mg/m2) was administered to 54 consecutive patients with advanced epithelial ovarian cancer (37 stage III and 17 stage IV). In 51 patients, surgery was performed prior to chemotherapy. Of the 37 stage III patients, 13 had only minimal residual disease after surgical debulking. The overall response rate was 69%, with 44% patients achieving clinical (cCR; n = 2) or pathological (pCR; n = 20) complete response. Median follow-up and overall survival time was 26 months, and median CR duration was 30 months. CR was achieved in 6 of 14 patients (43%) who were partial responders after five cycles of chemotherapy and had continued treatment for three to five more cycles. Severe bone marrow toxicity or renal function impairment was never observed, but eight patients presented peripheral signs of dose-related neurotoxicity. These findings indicate that CDDP and CTX in combination are an effective treatment for patients with advanced ovarian carcinoma, and can be administered with tolerable toxicity. In selected cases, prolonged chemotherapy administration can result in durable complete remissions.

AB - Chemotherapy with cisplatin (CDDP, 90 mg/m2) and cyclophosphamide (CTX, 600 mg/m2) was administered to 54 consecutive patients with advanced epithelial ovarian cancer (37 stage III and 17 stage IV). In 51 patients, surgery was performed prior to chemotherapy. Of the 37 stage III patients, 13 had only minimal residual disease after surgical debulking. The overall response rate was 69%, with 44% patients achieving clinical (cCR; n = 2) or pathological (pCR; n = 20) complete response. Median follow-up and overall survival time was 26 months, and median CR duration was 30 months. CR was achieved in 6 of 14 patients (43%) who were partial responders after five cycles of chemotherapy and had continued treatment for three to five more cycles. Severe bone marrow toxicity or renal function impairment was never observed, but eight patients presented peripheral signs of dose-related neurotoxicity. These findings indicate that CDDP and CTX in combination are an effective treatment for patients with advanced ovarian carcinoma, and can be administered with tolerable toxicity. In selected cases, prolonged chemotherapy administration can result in durable complete remissions.

UR - http://www.scopus.com/inward/record.url?scp=0025072764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025072764&partnerID=8YFLogxK

M3 - Article

C2 - 2161174

AN - SCOPUS:0025072764

VL - 13

SP - 199

EP - 203

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 3

ER -